This has been a great month for accruals. We earned 10.5 much needed treatment credits and 12.5 control credits. At this time, we are 10.9 treatment credits behind to be on track to meet our NCI target credits of 110 for this grant year. For control credits we are 5.6 credits above our NCI target of 80 for this grant year. We can still achieve our target accruals and really need to as it will help in getting our grant application approved this fall!

**NCI 6-month Accruals for Grant Year 2012-2013**

Below is a chart of the NCI 6-month accrual statistics (June 2012 – November 2012) for all CCOPs. At the end of November we were at 76% in meeting our treatment credits of 55 and at 92% in meeting our cancer control credits of 40 for 6 months. Last year we were at 93% in meeting our treatment accruals and 92% in meeting our accruals for the same time frame.

**New CRO Affiliations**

CRO is currently in negotiations to add the St. Louis CCOP and its affiliates to our CCOP. The St. Louis CCOP includes affiliates at St. Francis in Cape Girardeau and Good Samaritan in Mt. Vernon, Illinois. We are unsure at this time if the two affiliate sites will be joining us. Ozark Medical Center in West Plains has expressed an interest in joining CRO as well. This is exciting news for CRO. These affiliations have the potential of increasing our analytic cancer cases by 40%.

**CRO Principal Investigator (PI)**

Dr. Carolla has announced his plan to retire as CRO’s Principal Investigator on May 31, 2013. Under his guidance we received our 5-year NCI grant with a record score, added three new CRO affiliates and developed our CRO web site just to name a few accomplishments. We are grateful for his 5 years of leadership to CRO and wish him well as he moves into full retirement. The CRO Executive Board is seeking a new PI to lead CRO during this exciting time of growth and restructuring. Please let Marilyn Bauer know if you are interested or have questions. Her contact information is 269-4880 or Marilyn.Bauer@CoxHealth.com. She will schedule a time for candidates to meet with the CRO Executive Board.
New Studies Approved in January 2012
Opened at Cox and Mercy Springfield
GOG-1203 A Randomized Phase III Study of Standard Vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C)

Studies Permanently Closed to Enrollment at Cox & Mercy in January 2012
GOG 0230D A Phase II Evaluation of Pazopanib (NSC #737754, IND #75648) In the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
RTOG 0929 A Randomized Phase I/II Study of ABT-888 in Combination with Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma - Bevacizumab failure arm is closed permanently closed. Bevacizumab naïve arm is temporarily closed